Publications by authors named "Edward C Li"

Claim this Profile
C
Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
Jeanine A Flanigan, Marie Yasuda, Chi-Chang Chen, Edward C Li

Support Care Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spending on Antineoplastic Agents in the United States, 2011 to 2016.
Samuel J Hong, Edward C Li, Linda M Matusiak, Glen T Schumock

J Oncol Pract· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National trends in prescription drug expenditures and projections for 2018.
Glen T Schumock, JoAnn Stubbings, Michelle D Wiest, Edward C Li, Katie J Suda, Linda M Matusiak

Am J Health Syst Pharm· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National trends in prescription drug expenditures and projections for 2017.
Glen T Schumock, Edward C Li, Michelle D Wiest, Katie J Suda, JoAnn Stubbings, Linda M Matusiak

Am J Health Syst Pharm· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National trends in prescription drug expenditures and projections for 2016.
Glen T Schumock, Edward C Li, Katie J Suda, Michelle D Wiest, JoAnn Stubbings, Linda M Matusiak

Am J Health Syst Pharm· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy of annual prescription drug expenditure forecasts in AJHP.
Patricia L Hartke, Lee C Vermeulen, James M Hoffman, Nilay D Shah, Fred Doloresco, Edward C Li, Linda M Matusiak

Am J Health Syst Pharm· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations in the early development of biosimilar products.
Edward C Li, Richat Abbas, Ira A Jacobs, Donghua Yin

Drug Discov Today· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National trends in prescription drug expenditures and projections for 2015.
Glen T Schumock, Edward C Li, Katie J Suda, Michelle D Wiest, Joann Stubbings, Linda M Matusiak

Am J Health Syst Pharm· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National trends in prescription drug expenditures and projections for 2014.
Glen T Schumock, Edward C Li, Katie J Suda, Linda M Matusiak, Robert J Hunkler

Am J Health Syst Pharm· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Andrew D Zelenetz, Islah Ahmed, Edward Louis Braud, James D Cross, Nancy Davenport-Ennis, Scott Gottlieb, Philip E Johnson, Edward C Li

J Natl Compr Canc Netw· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Will risk evaluation and mitigation strategies ever be accepted?
Edward C Li

J Natl Compr Canc Netw· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A quick REMS update and a clinical focus.
Edward C Li

J Natl Compr Canc Netw· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring pharmacy and drug policy concerns.
Edward C Li

J Natl Compr Canc Netw· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights and perspectives in the clinical and operational management of cancer-related anemia.
Jennifer M Hinkel, Edward C Li, Stephen L Sherman

J Natl Compr Canc Netw· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.
Philip E Johnson, George Dahlman, Kirby Eng, Rekha Garg, Scott Gottlieb, Julie M Vose, Edward C Li

J Natl Compr Canc Netw· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary report: the development of the NCCN Comparative Therapeutic Index™ as a clinical evaluative process for existing data in oncology.
Edward C Li, Jessica DeMartino

J Natl Compr Canc Netw· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-induced QT-interval prolongation: considerations for clinicians.
Edward C Li, John S Esterly, Shaunte Pohl, Shane D Scott, Brian F McBride

Pharmacotherapy· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Task Force Report: Specialty Pharmacy.
Rowena N Schwartz, Kirby J Eng, Deborah A Frieze, Tracy K Gosselin, Niesha Griffith, Philip E Johnson, Edward C Li

J Natl Compr Canc Netw· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zoledronic acid: a new parenteral bisphosphonate.
Edward C Li, Lisa E Davis

Clin Ther· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis